Bavarian Nordic Enters Trials With HIV Multiantigen Vaccine
Bavarian Nordic has initiated a Phase I/II clinical study with its HIV vaccine candidate: MVA-BN HIV multiantigen.
Enrolment in a Phase I/II safety and immunogenicity study in 15 HIV-infected patients (CD4 counts >350 ul/ml) has begun in the United States.Â The first safety data is expected by the end of 2008 and immunogenicity data will be available during first half of 2009.
The MVA-BN HIV multiantigen vaccine encodes eight genes from HIV, including Nef and thus represents a more advanced vaccine candidate compared to Bavarian Nordic’s previous MVA-based HIV vaccine candidates, MVA HIV nef and MVA-BN HIV polytope. In previous clinical studies with MVA HIV nef, Bavarian Nordic has demonstrated proof-of-concept for the MVA technology’s ability to control HIV replication.
Full Story: Bavarian Nordic Enters Trials With HIV Multiantigen Vaccine
Source: Bavarian Nordic A/S